OGXI many catalysts here+p3 is continuing based on the pre-planned
interim futility analysis of the intent-to-treat population as reported on 8k(12/01/15)
As of September 30, 2015, our cash, cash equivalents and short-term investments increased to $65.9 million from $47.1 million
as of December 31, 2014.
·
Based on our current expectations, we believe that our cash, cash equivalents, and short-term investments will be sufficient to
fund our currently planned operations into the first quarter of 2017, which may include:
o
announcing AFFINITY trial results, including final results of the poor prognosis subpopulation by the end of 2015 and
final analysis for the ITT population in the second half of 2016, depending on timing of the event-driven final analysis;
o
announcing ENSPIRIT trial results, which could be available in the second half of 2016;
o
announcing Spruce trial results for the primary PFS endpoint in the first quarter of 2016;
o
announcing Borealis-2 trial results in 2016;
o
completing enrollment in the Pacific trial; and,
o
continuing enrollment in the Spruce-2 trial, formerly referred to as the Cedar Trial
many catalyst here,good reason the be a part of them,imo,while market cap is a less than $30.
News 
Market Data 
Discover 
